Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Thalassemia × Alemtuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4 Leukemia 4 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Thalassemia 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myeloproliferative Disorders 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Leukemia, Prolymphocytic 1 Kidney Transplantation 1 Kidney Neoplasms 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Carcinoma, Renal Cell 1

Interventions

fludarabine phosphate 1 fludarabine 1 Mesna 1 Cyclophosphamide 1 Busulfan 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡